Evaluation of the relationship between serum levels of VEGF and sVEGFR1 with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever

Journal of Medical Virology

Volumn 85, Issue 10, 2013, Pages 1794-1801

  Bakir, Mehmet ^a   Bakir, Sevtap ^a   Sari, Ismail ^a   Celik, Veysel Kenan ^a   Gozel, Mustafa Gokhan ^a   Engin, Aynur ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Mortality; Prognosis; SVEGFR1; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; D DIMER; FIBRINOGEN; LACTATE DEHYDROGENASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MALE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

CRIMEAN-CONGO HEMORRHAGIC FEVER; MORTALITY; PROGNOSIS; SVEGFR1; VEGF;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84881030056     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23666     Document Type: Article

References (33)

1. Alves BE, Montalvao SA, Aranha FJ, Lorand-Metze I, De Souza CA, Annichino-Bizzacchi JM, De Paula EV. 2011. Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: A prospective study. J Transl Med 9:23.
2. Ardalan MR, Tubbs RS, Chinikar S, Shoja MM. 2006. Crimean-Congo haemorrhagic fever presenting as thrombotic microangiopathy and acute renal failure. Nephrol Dial Transplant 21:2304-2307.
3. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. 2005. Turkish CCHF study group: Crimean-Congo hemorrhagic fever outbreak in Middle Anatolia: A multicenter study of clinical features and outcome measures. J Med Microbiol 54:385-389.
4. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343.
5. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220.
6. Bodur H, Akinci E, Onguru P, Uyar Y, Basturk B, Gozel MG, Kayaaslan BU. 2010. Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int J Infect Dis 14:e704-e707.
7. Cavaillon JM, Adib-Conquy M. 2005. Monocytes/macrophages and sepsis. Crit Care Med 33:S506-S509.
8. Cevik MA, Erbay A, Bodur H, Gülderen E, Baştuǧ A, Kubar A, Akinci E. 2008. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: Predictors of fatality. Int J Infect Dis 12:374-379.
9. Connolly-Andersen AM, Moll G, Andersson C, Akerström S, Karlberg H, Douagi I, Mirazimi A. 2011. Crimean-Congo hemorrhagic fever virus activates endothelial cells. J Virol 85:7766-7774.
10. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. 1992. The fmslike tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991.
11. Ergonul O. 2006. Crimean-Congo hemorrhagic fever. Lancet Infect Dis 6:203-214.
12. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. 2006. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: Severity criteria revisited. Clin Microbiol Infect 12:551-554.
13. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
14. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, Thuy TT, Tham VD, Nga CT, Ha TT, Ohmoto Y, Kikuchi M, Morita K, Yasunami M, Hirayama K, Watanabe N. 2012. Association of mast cell-derived VEGF and proteases in dengue shock syndrome. PLoS Negl Trop Dis 6:e1505.
15. Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell Signal 13:85-94.
16. Huckle WR, Roche RI. 2004. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem 93:120-132.
17. Kendall RL, Wang G, Thomas KA. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-328.
18. Lee M-C, Wei S-C, Tsai-Wu J-J, Wu CHH, Tsao PN. 2008. Novel PKC signaling is required for LPS-induced soluble Flt-1 expression in macrophages. J Leukoc Biol 84:835-841.
19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
20. Ozturk B, Kuscu F, Tutuncu E, Sencan I, Gurbuz Y, Tuzun H. 2010. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol 47:115-119.
21. Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M. 2005. Vascular endothelial growth factor is increased during the first 48hours of human septic shock and correlates with vascular permeability. Shock 24:508-512.
22. Sathupan P, Khongphattanayothin A, Srisai J, Srikaew K, Poovorawan Y. 2007. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection. Ann Trop Paediatr 27:179-184.
23. Seet RCS, Chow AWL, Quek AML, Chan YH, Lim ECH. 2009. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: A case-control study. Int J Infect Dis 13:e248-e253.
24. Shapiro NI, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak S, Ngo L, Aird WC. 2010. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 14:R182.
25. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, Ngo L, Angus DC, Aird WC. 2008. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock 29:452-457.
26. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. 2010. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol 84:11227-11234.
27. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. 1989. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 11:794-800.
28. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586.
29. Tsao PN, Chan FT, Wei SC, Hsieh WS, Chou HC, Su YN, Chen CY, Hsu WM, Hsieh FJ, Hsu SM. 2007. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med 35:1955-1960.
30. Tseng CS, Lo HW, Teng HC, Lo WC, Ker CG. 2005. Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 43:99-102.
31. Vorou R, Pierroutsakos IN, Maltezou HC. 2007. Crimean-Congo hemorrhagic fever. Curr Opin Infect Dis 20:495-500.
32. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. 1997. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420:28-32.
33. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. 2006. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203:1447-1458.